Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;27(3):149-154.
doi: 10.1097/MOH.0000000000000581.

Current and future gene therapies for hemoglobinopathies

Christian Brendel  1   2   3 , David A Williams  1   2   3
Affiliations
Review

Current and future gene therapies for hemoglobinopathies

Christian Brendel et al. Curr Opin Hematol. 2020 May.

Abstract

Purpose of review: In this work we briefly summarize the key features and currently available conventional therapies for the two main β-hemoglobinopathies, sickle cell disease (SCD) and β-thalassemia, and review the rapidly evolving field of novel and emerging genetic therapies to cure the disease.

Recent findings: Gene therapy using viral vectors or designer nuclease-based gene editing is a relatively new field of medicine that uses the patient's own genetically modified cells to treat his or her own disease. Multiple different approaches are currently in development, and some have entered phase I clinical studies, including innovative therapies aiming at induction of fetal hemoglobin.

Summary: Early short-term therapeutic benefit has been reported for some of the ongoing clinical trials, but confirmation of long-term safety and efficacy remains to be shown. Future therapies aiming at the targeted correction of specific disease-causing DNA mutations are emerging and will likely enter clinical testing in the near future.

PubMed Disclaimer

References

    1. Quinn CT, Miller ST. Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematol Oncol Clin North Am 2004; 18:1339–1354.
    1. Heeney MM. LD Z, VW C. Management of sickle cell disease. Comprehensive pediatric hospital medicine. Philadelphia:Elsevier; 2007. 731–737.
    1. Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med 2010; 363:2258–2260.
    1. Paulukonis ST, Eckman JR, Snyder AB, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep 2016; 131:367–375.
    1. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593–1599.

Publication types

MeSH terms